secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060210
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla Q3 net loss $33.3M; FDA backs registrational path for BA3011 in NSCLC
-----------------------------------------------------------------------------

- Net loss widened to $33.3M in Q3 2023 from $25.8M a year ago, driven by a 43% rise in R&D costs.
- Cash fell to $141.3M at Sep 30, down from $215.5M at Dec 31 2022; now expected to fund operations into 2H 2025.
- FDA supportive of registrational path for CAB-AXL-ADC (BA3011) in NSCLC; detailed Phase 2 data to be presented in early December.
- New partial responses observed with CAB-ROR2-ADC (BA3021) in melanoma and head & neck cancer at Phase 2.
- Phase 2 for CAB-CTLA-4 (BA3071) initiated with first patient in; Phase 1 data and R&D Day on Dec 13.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017023060210/0000950170-23-060210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017023060210/bcab-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer